display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negative
mBC - Triple negative (TNBC) - (neo)adjuvant (NA)mBC - Triple negative (TNBC) - 1st Line (L1)la/mBC - TNBC - L1 - all populationla/mBC - TNBC - L1 - PDL1 positivela/mBC - TNBC - L2 - all populationla/mBC - TNBC - L2 - PDL1 positivees-BC - Triple negatif (TNBC) - (neo)adjuvant (NA)es-BC - TNBC - NA - all populationes-BC - TNBC - NA - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment NSABP B-59/GBG 96-GeparDouze NSABP B-59/GBG 96-GeparDouze IMpassion-132 ... Alice IMpassion-132 ... TBCRC IMpassion-132 ... IMpassion-132 ...
atezolizumab plus carboplatin plus nab-paclitaxel NeoTrip Michel Angelo
atezolizumab plus carboplatin plus paclitaxel NCI 10013 NCI 10013
atezolizumab plus nab-paclitaxel IMpassion-130 ... IMpassion-130 ... IMpassion-031 ... IMpassion-031 ...
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide IMpassion-031 ...
atezolizumab plus paclitaxel IMpassion-131 ... IMpassion-131 ... ALEXANDRA/IMpassion-030
avelumab based treatment
avelumab alone A-Brave A-Brave Stratum A
camrelizumab based treatment
camrelizumab alone FUTURE-SUPER_immunomodulatory subtype
durvalumab based treatment
durvalumab alone GeparNuevo
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 ... KEYNOTE-119 PD-L1 positive ...
pembrolizumab plus SoC KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-355 ... KEYNOTE-522

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons